Literature DB >> 15823382

Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study.

Matthew J Burton1, Martin J Holland, Pateh Makalo, Esther A N Aryee, Neal D E Alexander, Ansumana Sillah, Hannah Faal, Sheila K West, Allen Foster, Gordon J Johnson, David C W Mabey, Robin L Bailey.   

Abstract

BACKGROUND: Community-wide mass antibiotic treatment is a central component of trachoma control. The optimum frequency and duration of treatment are unknown. We measured the effect of mass treatment on the conjunctival burden of Chlamydia trachomatis in a Gambian community with low to medium trachoma prevalence and investigated the rate, route, and determinants of re-emergent infection.
METHODS: 14 trachoma-endemic villages in rural Gambia were examined and conjunctival swabs obtained at baseline, 2, 6, 12, and 17 months. Mass antibiotic treatment with azithromycin was given to the community at baseline. C trachomatis was detected by qualitative PCR and individual infection load then estimated by real-time quantitative PCR.
FINDINGS: C trachomatis was detected in 95 (7%) of 1319 individuals at baseline. Treatment coverage was 83% of the population (1328 of 1595 people). The effect of mass treatment was heterogeneous. In 12 villages all baseline infections (34 [3%] of 1062 individuals) resolved, and prevalence (three [0.3%]) and infection load remained low throughout the study. Two villages (baseline infection: 61 [24%] of 257 individuals) had increased infection 2 months after treatment (74 [30%]), after extensive contact with other untreated communities. Subsequently, this value reduced to less than half of that before treatment (25 [11%]).
INTERPRETATION: Mass antibiotic treatment generally results in effective, longlasting control of C trachomatis in this environment. For low prevalence regions, one treatment episode might be sufficient. Infection can be reintroduced through contact with untreated populations. Communities need to be monitored for treatment failure and control measures implemented over wide geographical areas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15823382     DOI: 10.1016/S0140-6736(05)61029-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  72 in total

1.  Elimination of trachoma: are we in danger of being blinded by the randomised controlled trial?

Authors:  H R Wright; J E Keeffe; H R Taylor
Journal:  Br J Ophthalmol       Date:  2006-11       Impact factor: 4.638

2.  Trachoma: ancient scourge, disease elimination, and future research.

Authors:  Charles Knirsch
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

3.  The association between latrine use and trachoma: a secondary cohort analysis from a randomized clinical trial.

Authors:  Meron Haile; Zerihun Tadesse; Sintayehu Gebreselassie; Berhan Ayele; Teshome Gebre; Sun N Yu; Nicole E Stoller; Bruce D Gaynor; Travis C Porco; Paul M Emerson; Thomas M Lietman; Jeremy D Keenan
Journal:  Am J Trop Med Hyg       Date:  2013-09-03       Impact factor: 2.345

4.  Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.

Authors:  Sheila K West; Beatriz E Munoz; Harran Mkocha; Charlotte Gaydos; Thomas Quinn
Journal:  Ophthalmic Epidemiol       Date:  2015       Impact factor: 1.648

5.  Active trachoma and ocular Chlamydia trachomatis infection in two Gambian regions: on course for elimination by 2020?

Authors:  Emma M Harding-Esch; Tansy Edwards; Ansumana Sillah; Isatou Sarr; Chrissy H Roberts; Paul Snell; Esther Aryee; Sandra Molina; Martin J Holland; David C W Mabey; Robin L Bailey
Journal:  PLoS Negl Trop Dis       Date:  2009-12-22

6.  Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities.

Authors:  Matthew J Burton; Martin J Holland; Pateh Makalo; Esther A N Aryee; Ansumana Sillah; Sandra Cohuet; Angels Natividad; Neal D E Alexander; David C W Mabey; Robin L Bailey
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

7.  The development of an age-structured model for trachoma transmission dynamics, pathogenesis and control.

Authors:  Manoj Gambhir; Maria-Gloria Basáñez; Matthew J Burton; Anthony W Solomon; Robin L Bailey; Martin J Holland; Isobel M Blake; Christl A Donnelly; Ibrahim Jabr; David C Mabey; Nicholas C Grassly
Journal:  PLoS Negl Trop Dis       Date:  2009-06-16

Review 8.  The global burden of trachoma: a review.

Authors:  Matthew J Burton; David C W Mabey
Journal:  PLoS Negl Trop Dis       Date:  2009-10-27

9.  Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distribution.

Authors:  Takele Lakew; Wondu Alemayehu; Muluken Melese; Elizabeth Yi; Jenafir I House; Kevin C Hong; Zhaoxia Zhou; Kathryn J Ray; Travis C Porco; Bruce D Gaynor; Thomas M Lietman; Jeremy D Keenan
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25

10.  When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countries.

Authors:  Kathryn J Ray; Thomas M Lietman; Travis C Porco; Jeremy D Keenan; Robin L Bailey; Anthony W Solomon; Matthew J Burton; Emma Harding-Esch; Martin J Holland; David Mabey
Journal:  PLoS Negl Trop Dis       Date:  2009-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.